Youth suicide prevention: Does access to care matter?

Current Opinion in Pediatrics

Volumn 21, Issue 5, 2009, Pages 628-634

  Campo, John V ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Antidepressive agents; Health services accessibility; Mood disorders; Primary Healthcare; Suicide

Indexed keywords

ADOLESCENT; ADOLESCENT DISEASE; HEALTH CARE ACCESS; HUMAN; JUVENILE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SUICIDAL BEHAVIOR; SUICIDE;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; ANTIDEPRESSIVE AGENTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MENTAL HEALTH SERVICES; PSYCHOTHERAPY; SUICIDE; YOUNG ADULT;

EID: 73349107411     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32833069bd     Document Type: Review

References (57)

1. Bridge JA, Greenhouse JB, Weldon AH, et al. Suicide trends among youths aged 10 to 19 years in the United States, 1996-2005. JAMA 2008; 300: 1025-1026. This study demonstrates that recently observed increases in the suicide rate from 2003 to 2004 among US youth aged 10-19 years were unlikely to be single-year anomalies.
2. Gould MS, Greenberg T, Velting DM, Shaffer D. Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 2003; 42:386-405.
3. Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. J Child Psychol Psychiatry 2006; 47:372-394.
4. Brent DA, Perper JA, Moritz G, et al. Psychiatric risk factors for adolescent suicide: a case-control study. J Am Acad Child Adolesc Psychiatry 1993; 32:521-529. (Pubitemid 23149027)
5. Shaffer D, Gould MS, Fisher P, et al. Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry 1996; 53:339-348.
6. US Department of Health and Human Services. National strategy for suicide prevention: goals and objectives for action. Rockville, Maryland: US DHHS, Public Health Service; 2001.
7. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomized controlled trials submitted to the MHRA's safety review. BMJ 2005; 330:335.
8. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other a.ntidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790-792.
9. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8 (5 Pt 2):625-639.
10. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68:380-383.
11. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005; 73:139-145.
12. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82-91.
13. Brown GK, Ten Have T, Henriques GR, et al. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA 2005; 294:563-570.
14. Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006; 63:757-766.
15. Tarrier N, Taylor K, Gooding P. Cognitive-behavioral interventions to reduce suicide behavior. Behav Modif 2008; 32:77-108. A systematic review and meta-analysis of 28 studies examining the impact of CBT on suicidality.
16. Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997; 54:877-885.
17. Harrington R, Fudge H, Rutter M, et al. Adult outcomes of childhood and adolescent depression. II: Psychiatric status. Arch Gen Psychiatry 1990; 47:465-473.
18. Wood A, Trainor G, Rothwell J, et al. Randomized trial of group therapy for repeated deliberate self-harm in adolescents. J Am Acad Child Adolesc Psychiatry 2001; 40:1246-1253.
19. Huey SJ Jr, Henggeler SW, Rowland MD, et al. Multisystemic therapy effects on attempted suicide by youths presenting psychiatric emergencies. J Am Acad Child Adolesc Psychiatry 2004; 43:183-190.
20. Donaldson D, Spirito A, Esposito-Smythers C. Treatment for adolescents following a suicide attempt: results of a pilot trial. J Am Acad Child Adolesc Psychiatry 2005; 44:113-120.
21. Rotheram-Borus MJ, Piacentini J, Cantwell C, et al. The 18-month impact of an emergency room intervention for adolescent female suicide attempters. J Consult Clin Psychol 2000; 68:1081-1093.
22. Spirito A, Boergers J, Donaldson D, et al. An intervention trial to improve adherence to community treatment by adolescents after a suicide attempt. J Am Acad Child Adolesc Psychiatry 2002; 41:435-442.
23. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292:807-820. (Pubitemid 39079667)
24. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64:1132-1143.
25. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRIresistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901-913. A landmark study of treatment options for depressed youth who failed one trial of SSRI antidepressant treatment.
26. Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the Treatment for Adolescents with Depression Study (TADS). J Clin Psychiatry 2009; 70:741-747. An examination of suicidal events and their correlates from the important and influential TADS.
27. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRIresistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009; 166:418-426. An examination of suicidal adverse events that emerged during the TORDIA study.
28. Mann JJ, Apter A, Bertolote J, et al. Suicide prevention strategies: a systematic review. JAMA 2005; 294:2064-2074.
29. Alexopoulos GS, Reynolds CF, Bruce ML, et al. Reducing suicidal ideation and depression in older primary care patients: 24-month outcomes of the PROSPECT study. Am J Psychiatry 2009. [Epub ahead of print] Reports on 2-year follow-up from the Prevention of Suicide in Primary Care Elderly: Collaborative Trial (PROSPECT), which evaluated the impact of a care management intervention on suicidal ideation and depression in older primary care patients.
30. Bruce ML, Ten Have TR, Reynolds CF 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA 2004; 291:1081-1091.
31. Asarnow JR, Jaycox LH, Duan N, et al. Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: a randomized controlled trial. JAMA 2005; 293:311-319.
32. Pirkola A, Sund R, Sailas E, Wahlbeck K. Community mental-health services and suicide rate in Finland: a nationwide small-area analysis. Lancet 2009; 373:147-153. This study examined the relationship between suicide risk and different configurations of community mental health services in Finland.
33. De Leo D, Buono MD, Dwyer J. Suicide among the elderly: the long-term impact of a telephone support and assessment intervention in northern Italy. Br J Psychiatry 2002; 181:226-229.
34. Fleischmann A, Bertolote JM, Wasserman D, et al. Effectiveness of brief intervention and contact for suicide attempters: a randomized controlled trial in five countries. Bull World Health Organ 2008; 86:703-709. Reports on an international and multisite study sponsored by the World Health Organization that explored whether a brief intervention with ongoing contacts following a suicide attempt could prevent suicide deaths relative to treatment as usual. This study randomized 1867 suicide attempters and demonstrated that a brief and low-cost intervention significantly reduced deaths by suicide compared with usual care in low and middle-income countries.
35. Kapusta ND, Niederkrotenthaler T, Etzersdorfer E, et al. Influence of psychotherapist density and antidepressant sales on suicide rates. Acta Psychiatr Scand 2009; 119:236-242. The above is a European study that found antidepressant sales and the population density of psychotherapists to be negatively associated with suicide rates.
36. Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to healthcare access in the United States: an ecological study. J Clin Psychiatry 2006; 67:517-523.
37. Cooper SL, Lezotte D, Jacobellis J, et al. Does availability of mental health resources prevent recurrent suicidal behavior? An ecological analysis. Suicide Life Threat Behav 2006; 36:409-417.
38. Gibbons RD, Hur K, Dulal K, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62:165-172.
39. Isacsson G, Holmgren A, Osby U, Ahlner J. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. Acta Psychiatr Scand 2009; 120:37-44. This study reports on time trends in the detection of antidepressants and five 'control medications' in the forensic toxicological screening of 16 937 suicides and 33 426 controls in Sweden over a 10-year period, supporting the study hypothesis that the increased use of antidepressants has contributed to reductions in completed suicide.
40. Ludwig J, Marcotte DE, Norberg K. Antidepressants and suicide. J Health Econ 2009; 28:659-676. This study examined variations in SSRI sales in relation to those of other drugs and the rate of suicide in 26 countries, concluding that SSRIs are responsible for quantifiable reductions in the suicide rate.
41. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63:332-339.
42. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683-1696.
43. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164:1356-1363.
44. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164:884-891.
45. Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178:1005-1011. This study addresses the question of whether concerns regarding pediatric antidepressant use following the actions of regulatory agencies may have had unintended public health consequences.
46. Olfson M, Marcus SC, Druss BG, et al. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008; 65:94-101. This study reports on changes in antidepressant prescription rates in the wake of the FDA warnings on antidepressant use.
47. Olfson M, Shaffer D, Marcus SC, Greeberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60:978-982.
48. Gibbons RD, Hur K, Dulal K, et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163:1898-1904.
49. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18: 1119-1132.
50. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009; 180:291-297. A systematic review of observational studies of the relationship between SSRI exposure and suicide completions or attempts in youth, adults, and the elderly.
51. Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA 2005; 293:2487-2495.
52. Miller CL, Druss B. Datapoints: suicide and access to care. Psychiatr Serv 2001; 52:1566.
53. Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry 2002; 159:909-916.
54. Slap GB, Vorters DF, Chaudhuri S, Centor RM. Risk factors for attempted suicide during adolescence. Pediatrics 1989; 84:762-772.
55. Leon AC, Marzuk PM, Tardiff K, et al. Antidepressants and youth suicide in New York City, 1999-2002. J Am Acad Child Adolesc Psychiatry 2006; 45:1054-1058. (Pubitemid 44343060)
56. Søndergård L, Kvist K, Andersen PK, Kessing LV. Do antidepressants precipitate youth suicide? A nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry 2006; 15:232-240.
57. Stevens J, Wang W, Fan L, et al. Parental attitudes toward children's use of antidepressants and psychotherapy. J Child Adolesc Psychopharmacol 2009; 19:289-296. This study explores the attitudes of parents in an outpatient mental health clinic regarding the risks and benefits of both psychotherapy and antidepressants for depressed youth.